Herpes zoster in the context of immune reconstitution inflammatory syndrome in patients with rheumatic diseases: a single-center retrospective study

References

• Sun HY, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis. 2009;22(4):394–402. doi:10.1097/QCO.0b013e32832d7aff.
   PubMed Web of Science ®Google Scholar
• Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients. J Dermatol. 2018;45(1):3–9. doi:10.1111/1346-8138.14074.
   PubMed Web of Science ®Google Scholar
• Shiohara T, Kurata M, Mizukawa Y, et al. Recognition of immune reconstitution syndrome necessary for better management of patients with severe drug eruptions and those under immunosuppressive therapy. Allergol Int. 2010;59(4):333–343. doi:10.2332/allergolint.10-RAI-0260.
   PubMedGoogle Scholar
• Jevtović DJ, Salemović D, Ranin J, et al. The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy. HIV Med. 2005;6(2):140–143. doi:10.1111/j.1468-1293.2005.00277.x.
   PubMed Web of Science ®Google Scholar
• Furer V, Zisman D, Kibari A, et al. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford). 2021;60(SI):SI90–SI95. doi:10.1093/rheumatology/keab345.
   PubMedGoogle Scholar
• Hertel M, Heiland M, Nahles S, et al. Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. J Eur Acad Dermatol Venereol. 2022;36(8):1342–1348. doi:10.1111/jdv.18184.
   PubMed Web of Science ®Google Scholar
• Ota M. SARS-CoV-2 mRNA vaccination and subsequent herpes zoster: possible immune reconstitution by mRNA vaccination. JAAD Case Rep. 2022;23:166–167. doi:10.1016/j.jdcr.2022.02.035.
   PubMedGoogle Scholar
• Atzeni F, Gozza F, Riva A, et al. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus. Expert Opin Pharmacother. 2023;24(6):679–689. doi:10.1080/14656566.2023.2195050.
   PubMed Web of Science ®Google Scholar
• Jeong S, Choi S, Park SM, et al. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study. Arthritis Res Ther. 2022;24(1):180. doi:10.1186/s13075-022-02871-1.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370–1375. doi:10.1093/rheumatology/kel328.
   PubMed Web of Science ®Google Scholar
• Veetil BM, Myasoedova E, Matteson EL, et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2013;65(6):854–861. doi:10.1002/acr.21928.
   PubMed Web of Science ®Google Scholar
• Walter R, Hartmann K, Fleisch F, et al. Reactivation of herpesvirus infections after vaccinations? Lancet. 1999;353(9155):810. doi:10.1016/S0140-6736(99)00623-6.
   PubMed Web of Science ®Google Scholar
• Marra F, Parhar K, Huang B, et al. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020;7(1):ofaa005. doi:10.1093/ofid/ofaa005.
   PubMed Web of Science ®Google Scholar
• French MA. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART. AIDS Read. 1999;9(8):548. 54–55, 59–62.
   PubMedGoogle Scholar
• Fujita J. Immune reconstitution inflammatory syndrome in the lung in non-human immunodeficiency virus patients. Respir Investig. 2020;58(1):36–44. doi:10.1016/j.resinv.2019.11.001.
   PubMed Web of Science ®Google Scholar
• Harigai M, Mochida S, Mimura T, et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol. 2014;24(1):1–7. doi:10.3109/14397595.2013.852834.
   PubMed Web of Science ®Google Scholar
• Gupta M, Jafri K, Sharim R, et al. Immune reconstitution inflammatory syndrome associated with biologic therapy. Curr Allergy Asthma Rep. 2015;15(2):499. doi:10.1007/s11882-014-0499-4.
   PubMed Web of Science ®Google Scholar
• Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019;5(2):e001041. doi:10.1136/rmdopen-2019-001041.
   PubMed Web of Science ®Google Scholar
• Iwanaga J, Fukuoka H, Fukuoka N, et al. A narrative review and clinical anatomy of herpes zoster infection following COVID-19 vaccination. Clin Anat. 2022;35(1):45–51. doi:10.1002/ca.23790.
   PubMed Web of Science ®Google Scholar
• Lladó I, Fernández-Bernáldez A, Rodríguez-Jiménez P. Varicella zoster virus reactivation and mRNA vaccines as a trigger. JAAD Case Rep. 2021;15:62–63. doi:10.1016/j.jdcr.2021.07.011.
   PubMedGoogle Scholar
• Chung WS, Lin HH, Cheng NC. The incidence and risk of herpes zoster in patients with sleep disorders: a population-based cohort study. Medicine (Baltimore). 2016;95(11):e2195. doi:10.1097/MD.0000000000002195.
   PubMed Web of Science ®Google Scholar
• Wada-Shimosato Y, Tanoshima R, Hiratoko K, et al. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Transpl Infect Dis. 2019;21(3):e13061. doi:10.1111/tid.13061.
   PubMed Web of Science ®Google Scholar
• Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2023;75(3):449–464. doi:10.1002/acr.25045.
   PubMed Web of Science ®Google Scholar
• Tummala R, Abreu G, Pineda L, et al. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med. 2021;8(1):e000464. doi:10.1136/lupus-2020-000464.
   PubMed Web of Science ®Google Scholar